Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor. It was first discovered in 1993 and developed by Eli Lilly and Company as LY248686. Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder. It has since received approval for a variety of indications including the treatment of neuropathic pain, Generalized Anxiety disorder, osteoarthritis, and stress incontinence. Duloxetine continues to be investigated for the treatment of pain in cancer, surgery, and more. It is grouped under the following drug class(es): Psychotropic agents, Serotonin agents and SNRIs. Its therapeutic use is listed as antianxiety drugs, antidepressants, central nervous system (CNS) agents, migraine preventive agents and osteoarthritis agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Xeristar, Yentreve and Duloxetinum. Its PubChem CID is 60835.
Duloxetine
| CAS No | 116539-59-4 |
|---|---|
| Molecular Formula | C18H19NOS |
| Molecular Weight | 297.4 g/mol |
| Synonyms | (3S)-N-methyl-3-naphthalen-1-yloxy-3-thiophen-2-ylpropan-1-amine |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor. It was first discovered in 1993 and developed by Eli Lilly and Company as LY248686. Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder.
The listed CAS number is 116539-59-4.
The listed molecular formula is C18H19NOS.
The listed molecular weight is 297.4 g/mol.
(3S)-N-methyl-3-naphthalen-1-yloxy-3-thiophen-2-ylpropan-1-amine.
The source lists Xeristar, Yentreve and Duloxetinum.